Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FBXO31
REST API REST API
Homo sapiens
FBXO31 is differentially expressed in 129 experiments: 52 organism parts: bone marrow, cerebellum, ... (50 more);, 53 disease states: normal, myeloma, ... (51 more);, 42 cell types 183 cell lines 20 compound treatments and 43 other conditions.
Synonyms FBXO14, Fbx31, MGC15419, FBX14
Orthologs Fbxo31 (Mus musculus)   FBXO31 (Gallus gallus)   FBXO31 (Danio rerio)   FBXO31 (Bos taurus)   Fbxo31 (Rattus norvegicus)   fbxo31 (Xenopus laevis)   FBXO31 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, SCF ubiquitin ligase complex, cyclin catabolic process, cell cycle, cyclin binding, response to DNA damage stimulus, SCF-dependent proteasomal ubiquitin-dependent protein catabolic process, mitotic cell cycle G1/S transition DNA damage checkpoint
InterPro Term F-box_dom_cyclin-like
UniProt Accession Q5XUX0
Search EB-eye ENSG00000103264
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-8167, E-MTAB-37, E-AFMX-5, E-GEOD-803, E-GEOD-6573, ... (12 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-22152, E-GEOD-19639, E-GEOD-24147, E-GEOD-19480, ... (19 experiments)

Factor Value U/D Experiments
MCF-7
2
E-GEOD-19639, E-GEOD-20081
human foreskin fibroblast
1
E-GEOD-4219
Hep3B
1
E-MTAB-37
NCIH838
1
E-MTAB-37
SW1463
1
E-MTAB-37
HOS
1
E-MTAB-37
177 more value(s).


Cell type

studied in E-GEOD-18811, E-GEOD-20033, E-TABM-130, E-MEXP-1403, E-GEOD-20677, ... (19 experiments)

Factor Value U/D Experiments
dNK cell
1
E-GEOD-20499
human embryonic stem cell
1
E-GEOD-20033
spermatocyte
1
E-TABM-130
mononuclear cell
1
E-GEOD-7307
CD34 positive
1
E-GEOD-12662
lung carcinoma
1
E-GEOD-17347
36 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-5563, E-GEOD-22148, ... (28 experiments)

Factor Value U/D Experiments
subependymal giant cell astrocytoma
1
E-MEXP-2351
colorectal cancer
1
E-GEOD-15960
glioblastoma
1
E-GEOD-4290
carcinoma
1
E-MTAB-37
NDV
1
E-GEOD-18791
adenoma
1
E-GEOD-15960
47 more value(s).


Compound treatment

studied in E-MEXP-1601, E-GEOD-7400, E-GEOD-3284, E-GEOD-15205, E-TABM-782, ... (12 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
none
2
3
E-MEXP-1958, E-TABM-868, E-TABM-782, E-GEOD-7400, E-MEXP-1601 ... (5 experiments)
control
1
E-GEOD-3284
DMSO
1
E-MEXP-1561
interferon-gamma + lipopolysaccharide
1
E-GEOD-7307
Cxcl12
1
E-GEOD-7307
14 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
DMSO
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-20499, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-MEXP-2359

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22148, E-GEOD-21138

Estrogen receptor status
studied in E-GEOD-6532

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-20847

Genotype
studied in E-GEOD-17476, E-TABM-868, E-TABM-601, E-GEOD-17347, E-MEXP-1403 ... (5 experiments)

Growth condition
studied in E-MEXP-2657, E-GEOD-10315

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-176, E-MEXP-2069, E-GEOD-19330, ... (16 experiments)

Infection
studied in E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-12662

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-MEXP-1403

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-18791

RNAi
studied in E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

Stimulation
studied in E-GEOD-11886

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-MEXP-973

Tumor grading
studied in E-GEOD-4271

Processing time: 0.461 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM